Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ENLV
ENLIVEX THERAPEUTICS LTD.
NASDAQ
$1.35
▼ DOWN 8.47% (-0.13)

KEY STATISTICS

Market Cap$22.72 M
52w High$27.15
52w Low$1.34
Dividend Yield—
Frequency—
P/E—
Volume529.95K
Shares Out.16.83M

COMPANY

LEADERSHIP

Oren Hershkovitz
CHIEF EXECUTIVE
Oren Hershkovitz

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 31, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
34

PRICE TARGET

Target High$15.00
Target Low$15.00
Target Median$15.00
Target Consensus$15.00

UPCOMING EARNINGS

DateDec 7, 2026
DayMonday
Rev. Est.—
DEC
7
MON

SPLIT RECORD

DATETYPERATIO
2026-07-09Reverse1:15
2019-03-06Reverse1:8
2017-09-25Reverse1:5

PRICE

$1.35 ▼ DOWN 8.47% (−$0.13)
OVERLAYS
$1.35$1.42$1.50$1.579:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.35

About Enlivex Therapeutics Ltd.

https://www.enlivex.com ↗

Enlivex Therapeutics Ltd., founded in 2005 in Nes Ziona, Israel, is a clinical-stage company developing Allocetra, a macrophage reprogramming immunotherapy for sepsis and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT ENLIVEX THERAPEUTICS LTD. IS KNOWN FOR

Allocetra™
Allocetra™

Allocetra™ by Enlivex Therapeutics is an off-the-shelf cell therapy that reprograms macrophages to restore immune balance, currently in clinical trials for sepsis and osteoarthritis.

COMPETITORS

COMPETITOR
ALLO COMPARE
FATE COMPARE
MESO COMPARE
PLUR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
IZRL
0.85% · 2.4M

INSTITUTIONAL OWNERSHIP

SHARES OWNED
31.13%
HOLDERS
47
TOP 12 OF 47 · RANKED BY POSITION SIZE
Diametric Capital, LP
1.5M sh · $1.38M
Armistice Capital, LLC
1.4M sh · $1.58M
Ark Investment Management LLC
628.3K sh · $584.39K
Renaissance Technologies LLC
313.6K sh · $220.54K
Citizens Financial Group Inc/Ri
231.4K sh · $240.68K
Prelude Capital Management, LLC
225.7K sh · $209.96K
Morgan Stanley
200.6K sh · $141.08K
Two Sigma Investments, LP
195.1K sh · $137.21K
Hrt Financial LP
154.0K sh · $108K
Ubs Group AG
138.3K sh · $128.65K
Bank Of America Corp /De/
130.4K sh · $121.27K
Jpmorgan Chase & Co
125.9K sh · $113.35K

RATINGS SNAPSHOT

Overall rating: S-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity5
Return On Assets5
Debt To Equity5
Price To Earnings3
Price To Book5
Overall Score5

INSIDER TRADES

★
DIRECTOR
NOVIK SHAI A
— · 133.0K shares
2019-06-01
★
OFFICER: CHIEF MEDICAL OFFICER
Galamidi Einat
— · 10.0K shares
2025-11-24
★
OFFICER: CHIEF EXECUTIVE OFFICER
Hershkovitz Oren
— · 150.0K shares
2023-11-16
★
OFFICER: CHIEF EXECUTIVE OFFICER
Hershkovitz Oren
— · 60.0K shares
2025-11-24

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
HOLD 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY D. Boral Capital HOLD

SECTORS PEERS

PEERPRICE
NRXS$6.00COMPARE
LSTA$1.69COMPARE
NRSN$0.42COMPARE
PASG$4.52COMPARE
GDTC$0.92COMPARE
NCNA$1.76COMPARE
XCUR$1.29COMPARE
CVKD$1.54COMPARE